Related references
Note: Only part of the references are listed.PREVENT: A Randomized, Placebo-controlled Crossover Trial of Avexitide for Treatment of Postbariatric Hypoglycemia
Colleen M. Craig et al.
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM (2021)
Rate of Serious Adverse Events Associated with Diazoxide Treatment of Patients with Hyperinsulinism
Paul Thornton et al.
HORMONE RESEARCH IN PAEDIATRICS (2019)
Genetic characteristics of patients with congenital hyperinsulinism
Mary Ellen Vajravelu et al.
CURRENT OPINION IN PEDIATRICS (2018)
Incretin hormones: Their role in health and disease
Michael A. Nauck et al.
DIABETES OBESITY & METABOLISM (2018)
Liraglutide ameliorates palmitate-induced insulin resistance through inhibiting the IRS-1 serine phosphorylation in mouse skeletal muscle cells
Z. Li et al.
JOURNAL OF ENDOCRINOLOGICAL INVESTIGATION (2018)
Prevalence of Adverse Events in Children With Congenital Hyperinsulinism Treated With Diazoxide
Adriana Herrera et al.
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM (2018)
Population pharmacokinetics of exendin-(9-39) and clinical dose selection in patients with congenital hyperinsulinism
Chee M. Ng et al.
BRITISH JOURNAL OF CLINICAL PHARMACOLOGY (2018)
Insulin's direct hepatic effect explains the inhibition of glucose production caused by insulin secretion
Dale S. Edgerton et al.
JCI INSIGHT (2017)
Postprandial Hypoglycemia in Children after Gastric Surgery: Clinical Characterization and Pathophysiology
Andrew C. Calabria et al.
HORMONE RESEARCH IN PAEDIATRICS (2016)
Liraglutide prevents microvascular insulin resistance and preserves muscle capillary density in high-fat diet-fed rats
Weidong Chai et al.
AMERICAN JOURNAL OF PHYSIOLOGY-ENDOCRINOLOGY AND METABOLISM (2016)
Perspective on the Genetics and Diagnosis of Congenital Hyperinsulinism Disorders
Charles A. Stanley
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM (2016)
Long-term medical treatment in congenital hyperinsulinism: a descriptive analysis in a large cohort of patients from different clinical centers
Alena Welters et al.
ORPHANET JOURNAL OF RARE DISEASES (2015)
Genotype and Phenotype Correlations in 417 Children With Congenital Hyperinsulinism
K. E. Snider et al.
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM (2013)
GLP-1 Receptor Antagonist Exendin-(9-39) Elevates Fasting Blood Glucose Levels in Congenital Hyperinsulinism Owing to Inactivating Mutations in the ATP-Sensitive K+ Channel
Andrew C. Calabria et al.
DIABETES (2012)
Gastric Bypass Surgery Enhances Glucagon-Like Peptide 1-Stimulated Postprandial Insulin Secretion in Humans
Marzieh Salehi et al.
DIABETES (2011)
Differential Effect of Sham Feeding on Meal Glucose Tolerance in Hypoglycemic vs. Asymptomatic Individuals after Gastric Bypass Surgery
Marzieh Salehi et al.
DIABETES (2011)
Minimal model assessment of hepatic insulin extraction during an oral test from standard insulin kinetic parameters
M. Campioni et al.
AMERICAN JOURNAL OF PHYSIOLOGY-ENDOCRINOLOGY AND METABOLISM (2009)
Exenatide Sensitizes Insulin-Mediated Whole-Body Glucose Disposal and Promotes Uptake of Exogenous Glucose by the Liver
Dan Zheng et al.
DIABETES (2009)
Glucagon-like peptide 1 (GLP-1) as a new therapeutic approach for Type 2-diabetes
M. A. Nauck et al.
EXPERIMENTAL AND CLINICAL ENDOCRINOLOGY & DIABETES (2009)
Exendin-(9-39) corrects fasting hypoglycemia in SUR-1-/- mice by lowering cAMP in pancreatic β-cells and inhibiting insulin secretion
Diva D. De Leon et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2008)
Protein-sensitive hypoglycemia without leucine sensitivity in hyperinsulinism caused by KATP channel mutations
Shannon H. Fourtner et al.
JOURNAL OF PEDIATRICS (2006)
The oral glucose minimal model: Estimation of insulin sensitivity from a meal test
C Dalla Man et al.
IEEE TRANSACTIONS ON BIOMEDICAL ENGINEERING (2002)
Accurate measurement of endogenous insulin secretion does not require separate assessment of C-peptide kinetics
RM Watanabe et al.
DIABETES (2000)
Share Paper
